IceCure Medical (ICCM) Current Deferred Revenue (2022 - 2025)

IceCure Medical (ICCM) has 4 years of Current Deferred Revenue data on file, last reported at $255000.0 in Q4 2025.

• On a quarterly basis, Current Deferred Revenue fell 23.65% year-over-year to $255000.0 in Q4 2025; TTM through Dec 2025 was $255000.0, a 23.65% decrease from a year earlier, with the FY2025 full-year figure at $255000.0, down 23.65% from the prior year.
• Current Deferred Revenue for Q4 2025 stood at $255000.0, down from $334000.0 in the prior quarter.
• Over the last five years, Current Deferred Revenue for ICCM reached as high as $646000.0 in Q4 2022 and fell as low as $187000.0 in Q4 2023.
• Historically, Current Deferred Revenue has averaged $355500.0 across 4 years, with a median of $294500.0 in 2024.
• Across the five-year window, Current Deferred Revenue slumped 71.05% in 2023 and soared 78.61% in 2024, its largest moves.
• Year by year, Current Deferred Revenue stood at $646000.0 in 2022, then slumped by 71.05% to $187000.0 in 2023, then surged by 78.61% to $334000.0 in 2024, then decreased by 23.65% to $255000.0 in 2025.
• Per Business Quant data, the three most recent Current Deferred Revenue figures were $255000.0 in Q4 2025, $334000.0 in Q4 2024, and $187000.0 in Q4 2023.